Does acting out your dreams mean you will get Parkinson's?

Does acting out your dreams mean you will definitely get Parkinson's?

An eventual diagnosis of Parkinson's disease is not inevitable. A meta-analysis of longitudinal studies tracking people who act out their dreams found that while the risk of developing some form of brain disease was 33.5% at five years and 96.6% at 14 years, only 43% of participants developed Parkinson's disease. Another 25% developed dementia with Lewy bodies.

Many people who act out their dreams transition to other neurological conditions. A multicentre study by the International RBD Study Group tracked 1,280 patients with idiopathic REM sleep behaviour disorder, which is defined as acting out dreams without other known neurological issues. Over an average of 4.6 years, 352 participants transitioned to a neurological syndrome, with 56.5% developing parkinsonism first (including 4.5% with multiple system atrophy) and 43.5% developing dementia first.

Common medications and weak diagnostic methods limit these findings. Antidepressants, especially selective serotonin reuptake inhibitors, can cause dream enactment, but a major meta-analysis could not separate drug-induced cases from primary sleep disorders because the original trials lacked medication data. Additionally, a systematic review of eight studies evaluating sleep disturbances in Parkinson's found that only three used video-polysomnography, which is the gold-standard sleep laboratory test, meaning many studies relied on simple, less accurate questionnaires.

Is all dream enactment actually REM sleep behaviour disorder?

A formal diagnosis requires objective proof of lost muscle paralysis. To confirm isolated REM sleep behaviour disorder, where a person acts out dreams, a patient must undergo polysomnography, which is an overnight sleep monitoring test. Clinicians look for REM sleep without atonia, which is the failure of the brain to temporarily paralyse the muscles during rapid eye movement sleep, defined in trials as active chin muscle tension for more than 7.5% of this sleep stage.

True dream enactment involves complex, violent movements rather than simple sounds. Occasional laughing, singing, or minor gestures can happen to anyone, but the clinical disorder requires a history of coordinated, violent actions such as punching, kicking, or biting. For example, a trial of 34 patients with Lewy body dementia had to use systematic video analysis of sleep periods to objectively rate these complex movements and vocalisations.

Antidepressant medications can mimic the disorder's symptoms. Nobody has tested patients with sleep studies both before and after starting antidepressants, so nobody knows if these drugs cause a separate issue or simply unmask an existing brain condition. In a North American study of 361 participants, only 5.4% of the 56 participants with isolated REM sleep behaviour disorder believed their symptoms were drug-related, compared to 25.2% of the 305 participants who had additional neurological decline.

If a sleep study confirms REM sleep behaviour disorder, what do long-term cohorts show?

Long-term progression rates are not settled for all time points. In a study of 1,280 patients across 24 international centres, the risk of transitioning to a neurological disease was 31.3% after 5 years and 60.2% after 10 years. Researchers could not calculate a 15-year risk because only 28 patients remained disease-free and under observation past 12 years, though the overall conversion risk reached 73.5% at 12 years.

A separate meta-analysis of multiple studies reports different timelines. This synthesis estimated the risk of developing a neurodegenerative disease to be 33.5% at 5 years, 82.4% at 10.5 years, and 96.6% at 14 years. Across these pooled studies, 43% of patients who converted developed Parkinson's disease, while 25% developed dementia with Lewy bodies.

We lack long-term data for patients with strictly isolated sleep symptoms. The North American Prodromal Synucleinopathy Consortium recruited 361 participants with sleep-study-confirmed REM sleep behaviour disorder, but only 56 had truly isolated symptoms without other neurological signs at baseline. Because this consortium is in its early stages, it has only published baseline data and has not yet reported how many of these strictly isolated patients convert over time.

Can tests predict who will convert and how long it will take?

A fading sense of smell is an early sign, but its predictive value is inconsistent. A meta-analysis of 123 studies of people with the sleep disorder found that loss of smell carried a 2.78 hazard ratio for converting to Parkinson's, while another meta-analysis of prospective studies found that impaired odour identification increased the risk more than fourfold. However, a systematic review of olfactory testing pooling 23 studies from 13 countries showed wide inconsistency, with diagnostic specificity ranging from 43% to 86% when trying to tell Parkinson's apart from vascular parkinsonism.

Colour vision and autonomic symptoms track different aspects of progression. A multicentre study of 336 patients with Lewy body disease found that colour vision testing predicted future dementia but failed to predict motor parkinsonism. For autonomic symptoms, a systematic review of 9 studies following 900 people with pure autonomic failure found that 30% developed a central nervous system disorder over an average of 6.4 years, with 7% developing Parkinson's at a slow rate of 1.35% per year.

Dopamine brain scans do not offer absolute certainty. In a study of 80 subjects carrying the G2019S LRRK2 gene, which mentioned trial registrations NCT01089270 and NCT01089283, one of three carriers who developed motor symptoms had normal scans both before and after clinical symptoms appeared. Furthermore, in an analysis of 50 patients with suspected Parkinson's and normal scans tracked for two years, only 13 had their Parkinson's diagnosis confirmed, while 37 were found to have other conditions.

Is there any proven therapy to stop or delay conversion?

No completed clinical trials show a therapy that can slow or stop progression. All previous neuroprotective trials have failed because they were conducted in patients with fully established brain diseases where damage was already too advanced. Two active trial registrations, which are a University of Zurich registration from 2026 testing deep sleep slow wave enhancement and a Skane University Hospital registration from 2021 investigating disease mechanisms, have not yet reported any results.

Standard treatments for sleep symptoms do not protect the brain. Symptom therapies like clonazepam and melatonin do not stop brain cell loss or the accumulation of toxic proteins. A four-week randomised trial of 40 patients with Parkinson's and the sleep disorder found no significant difference in symptoms between the 20 patients taking 0.5 mg of clonazepam daily and the 20 taking a placebo, while presenting risks of falls and drowsiness.

Melatonin has also failed to show objective benefits in rigorous trials. An eight-week randomised trial of 30 patients found no significant difference in outcomes, with patients experiencing 3.4 sleep events per week on 4 mg of melatonin compared to 3.6 on a placebo. A larger systematic review and meta-analysis confirmed that while melatonin is well-tolerated, it has no significant impact on objective sleep measurements or overall sleep behaviour scores.

What this does not show

Decisive proof is lacking because key trials are small, uncontrolled, or plagued by weak methods. The standard treatment, clonazepam, has surprisingly weak scientific support: a 2025 systematic review of 27 studies found major methodological limitations, including a lack of objective measurements and heavy reliance on retrospective reports. Promising alternatives rest on tiny, unreplicated pilot studies, such as an open-label study of ramelteon in only 35 patients that lacked a control group, a crossover trial of safinamide in 30 patients, and an 18-patient study of 5-hydroxytryptophan.

Cannabidiol has failed to outperform a placebo in clinical testing. Despite early anecdotal hopes, a randomised, double-blind, placebo-controlled trial of 33 patients found no symptom reduction, and a post hoc analysis of 18 of these patients showed cannabidiol failed to ease restless legs syndrome. A separate trial of 61 patients testing a combination of cannabidiol and tetrahydrocannabinol found no benefit, instead showing a trend toward worsened sleep and cognition compared to a placebo.

Even the link between dream enactment and brain disease remains uncertain. A meta-analysis pooling 28 studies with 6,869 patients found that the prevalence of the sleep disorder in Parkinson's was 42.3%, meaning most people with Parkinson's never experience it. Furthermore, a meta-analysis of eight studies involving 6,280 people detected publication bias, indicating that researchers may have published positive results more frequently, which artificially inflates how closely dream enactment and Parkinson's disease are linked.

While this research outlines the statistical links and diagnostic limitations of dream enactment, it cannot determine your individual risk or diagnose the cause of your sleep symptoms. A specialist sleep clinician can help you interpret these findings in the context of your own health history and arrange objective testing if needed.